Endoscopic endonasal resection and radiotherapy as treatment for skull base chordomas.

BACKGROUND

The role of endonasal endoscopic surgery and radiotherapy in the treatment of skull base chordomas remains unclear.

OBJECTIVE

We investigated the effect of endonasal endoscopic surgery and radiotherapy as treatment for skull base chordomas.

METHOD

We investigated 46 patients (2006-2018) treated at the Affiliated Eye Ear Nose and Throat Hospital, Fudan University. We documented demographics, clinical presentation, operative resection, complications, postoperative radiotherapy, follow-up time, and survival in all patients.

RESULT

Complete tumour resection was performed in 18 (39.1%), subtotal tumour resection in 16 (34.8%), and partial tumour resection in 12 (26.1%) patients. Most common clinical manifestations included nasal obstruction (41%), headaches (30%), and visual impairment (20%). The median duration of progression-free survival (PFS) and overall survival (OS) was 21.5 and 33.5 months, respectively. Primary vs. recurrent disease ( = .043), partial resection (PR) vs. subtotal resection (STR) ( = .006), STR vs. gross total resection (GTR) ( = .020), GTR vs. PR ( = .001), and complicated vs. uncomplicated status ( = .002) were significantly associated with PFS. Primary vs. recurrent disease ( = .002), PR vs. STR ( = .001), GTR vs. PR ( = .001), surgery alone vs. surgery concomitant with radiotherapy ( = .048), and complicated vs. uncomplicated status ( = .017) were significantly associated with OS.

CONCLUSION

Surgery is the primary treatment for chordoma; higher tumour resection rates are associated with higher OS and PFS. Surgeons should aim to resect as much tumour as is safely possible. Postoperative radiotherapy is useful adjuvant treatment to improve OS, and IMRT serves as an effective alternative to PBRT.The optimal radiotherapeutic technique is determined by cost, accessibility, availability of the modality, and tumour volume.